Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical has announced that its innovative drug, TQC3721 inhalation suspension, has received approval from China’s National Medical Products Administration to commence a phase III clinical study for COPD treatment. This drug, a PDE3/4 inhibitor, offers both bronchodilatory and anti-inflammatory effects, potentially improving treatment outcomes for COPD patients. The approval marks a significant step in the company’s research and development efforts, positioning it as a leader in COPD treatment innovation. The study will evaluate the drug’s efficacy and safety across a broader patient base, which could enhance its market positioning and provide a competitive edge in the global pharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a pharmaceutical company involved in the development of innovative drugs, focusing on treatments for chronic diseases such as chronic obstructive pulmonary disease (COPD). The company operates in the healthcare industry, offering products that target significant public health challenges.
YTD Price Performance: 42.19%
Average Trading Volume: 110,263,751
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.38B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.